newsfilter
← Latest News
Business Wire·

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

ABCL575 is an Fc-silenced, half-life extended investigational antibody therapy that is being developed for the treatment of atopic dermatitis AbCellera (NASDAQ:ABCL) today announced it has dosed the first participants